Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.45 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.45 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.45 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | TPMT | P51580 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | LDHA | P00338 | 1/20 | 0.41 |
| ▸ | LDHB | P07195 | 1/20 | 0.41 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | DAO | P14920 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL597751 | 0.89 | ALDH1A1 (0.57) | SMN1; SMN2ALDH1A1MAPK1CYP3A4AKR1C4 | |
| SCHEMBL111202 | 0.84 | AKR1C4 (0.54) | SMN1; SMN2ALDH1A1CYP3A4AKR1C4AKR1C3 | |
| SCHEMBL12233904 | 0.83 | KMT2A (0.43) | SMN1; SMN2ALDH1A1MAPK1CYP3A4AKR1C4 | |
| SCHEMBL9737304 | 0.83 | ALDH1A1 (0.52) | SMN1; SMN2ALDH1A1MAPK1CYP3A4ACHE | |
| SCHEMBL1301827 | 0.81 | AKR1C4 (0.52) | SMN1; SMN2ALDH1A1CYP3A4AKR1C4AKR1C3 | |
| SCHEMBL28392002 | 0.81 | AKR1C4 (0.52) | SMN1; SMN2ALDH1A1CYP3A4AKR1C4AKR1C3 | |
| SCHEMBL5878784 | 0.81 | AKR1C4 (0.52) | SMN1; SMN2ALDH1A1CYP3A4AKR1C4AKR1C3 | |
| Hydrochloric Acid SCHEMBL2512939 | 0.81 | AKR1C4 (0.52) | SMN1; SMN2ALDH1A1CYP3A4AKR1C4AKR1C3 | |
| SCHEMBL11209199 | 0.81 | CYP3A4 (0.64) | SMN1; SMN2ALDH1A1MAPK1CYP3A4AKR1C4 | |
| SCHEMBL3922931 | 0.81 | POLB (0.53) | SMN1; SMN2ALDH1A1MAPK1CYP3A4LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106588606-A | Method of continuously oxidizing 3,5-dichlorotoluene for producing 3,5-dichlorobenzaldehyde | 常州大学 | 2017-04-26 | — | — | CN | disclosed |
| WO-2013030358-A1 | GLYCINE B ANTAGONISTS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2013-03-07 | — | — | WO | disclosed |
| US-20100298366-A1 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | GENZYME CORPORATION (US) | 2010-11-25 | — | — | US | disclosed |
| US-7790747-B2 | Chemokine receptor binding compounds | GENZYME CORPORATION (US) | 2010-09-07 | — | — | US | disclosed |
| US-20090099205-A1 | Chemokine receptor binding compounds | GENZYME CORPORATION | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298366-A1 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | CCR5, CXCR3, CCL5 | SMN1; SMN2 4838/4885ALDH1A1 3358/4885MAPK1 1005/4885 |
| US-20090099205-A1 | Chemokine receptor binding compounds | CCR5, CXCR3, CCL5 | SMN1; SMN2 4838/4885ALDH1A1 3358/4885MAPK1 1005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.